Capital Cell is the world’s leading alternative investment platform for early-stage biotech and life science companies. Selected by experts, backed by visionaries, Capital Cell gives you the chance to shape the future of health, one investment at a time. Read More

The SAB was enthusiastic about our candidate V4C232 as new treatment in cirrhotic refractory ascites* and confirmed there is no new other therapeutic option, so far. SAB agreed with the proposal of V4CURE to consider the refractory ascites definition previously used in clinical trial. (*) Definition of diuretic-resistant refractory ascites: ascites that cannot be mobilized or...Read More

More info here: https://informaconnect.com/bioeurope-spring/Read More

A rat experimental model of desmopressin-induced hyponatremia, ex vivo mice model of kidney cysts, and mice orthologous model of ADPKD* were used to validate V4C232 (MQ232) efficacy in these pathologies. (*) ADPKD: Autosomal Dominant Polycystic Kidney Disease MQ232, A Snake Toxin Derivative for Treatment of Hyponatremia and Polycystic Kidney Diseases – PubMedRead More

Effectiveness of MQ232 in an orthologous ADPKD mouse model. Xiaofang Wang, Li Jiang, Kavini Nanayakkara, Jinghua Hu, Nicolas Gilles, Vicente E. Torres.Read More